Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

1 to 25 of 254 results

Genesis One Nucleus 2014: personalized medicine and big data

Genesis One Nucleus 2014: personalized medicine and big data

10-12-2014

In the opening sessions at the Genesis One Nucleus 2014 conference in London yesterday, the main themes…

Evidence-based medicineHealth Medical PharmaInterviewsJohnson & JohnsonPharmaceuticalResearch

Astellas Xtandi approved in Europe for new indication; Janssen deal update

03-12-2014

Japanese pharma major Astellas Pharma has received European Commission approval for a variation to amend…

Anti-Arthritics/RheumaticsASP015KAstellas PharmaEuropeJanssen BiotechJohnson & JohnsonLicensingMedivationOncologyPharmaceuticalRegulationXtandi

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Despite patent cliffs, pharma market shows signs of stability

19-11-2014

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies…

Biogen IdecBoehringer IngelheimFinancialJohnson & JohnsonPatentsPfizerPharmaceutical

New Zealand proposal for sole supply of Remicade in DHB hospitals

New Zealand proposal for sole supply of Remicade in DHB hospitals

31-10-2014

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesceftaroline fosamilFinancialJanssen-CilagJohnson & JohnsonNew ZealandPharmaceuticalPricingRemicade

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

Medivir concludes Swedish agreement on Olysio-based treatment for hepatitis C

31-10-2014

Swedish drugmaker Medivir says it has entered into an agreement with Swedish county councils regarding…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalPricingRegulationSweden

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

31-10-2014

Xtandi (enzalutamide), produced by biopharma company Medivation and Japanese drug major Astellas Pharma…

AstellasDecision Resources GroupJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Non-Hodgkin lymphoma market to grow to $9.2 billion

Non-Hodgkin lymphoma market to grow to $9.2 billion

29-10-2014

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research.

Celgene Corp.EuropeGilead SciencesImbruvicaJanssen BiotechJohnson & JohnsonMabTheraOncologyPharmaceuticalPharmacyclicsResearchRevlimidRocheUSAVelcadeZydelig

Pharmacyclics files Imbruvica sNDA for Waldenstrom’s macroglobulinemia

20-10-2014

US drugmaker Pharmacyclics has submitted a supplemental New Drug Application to the US Food and Drug…

ImbruvicaJanssen BiotechJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulationUSA

Pharmacyclics’ Imbruvica gains EU approval for two blood cancers

17-10-2014

US drugmaker Pharmacyclics has received marketing approval from the European Commission for Imbruvica…

EuropeImbruvicaJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsRegulation

Public-private partnerships vital to advance Ebola treatment pipeline, says analyst

16-10-2014

In the battle against Ebola, incentives from governments and health care policymakers have been and will…

Anti-viralscAd3-ZEBOVGlaxoSmithKlineJohnson & JohnsonMapp BiopharmaceuticalNewLink GeneticsPharmaceuticalResearch

Johnson & Johnson third-qtr results beat analysts’ expectations

14-10-2014

US health care giant Johnsons & Johnson, the first in the sector to report third-quarter 2014 financial…

FinancialJohnson & JohnsonPharmaceutical

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma

30-09-2014

US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

UK NICE consults on draft guidance for hepatitis C drug Olysio

UK NICE consults on draft guidance for hepatitis C drug Olysio

18-09-2014

In draft guidance published today UK drugs watchdog the National Institute for Health and Care Excellence…

Anti-viralsJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulationUK

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

Added benefit for certain patients found by IQWiG with Janssen’s Olysio

15-09-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

Anti-viralsGermanyJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulation

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

Johnson & Johnson fast-tracking its Ebola efforts with Crucell and Bavarian Nordic

04-09-2014

US health care giant Johnson & Johnson will fast-track the development of an Ebola vaccine in response…

Antibiotics and Infectious diseasesBavarian NordicCrucellEbolaJohnson & JohnsonMicrobiologyPharmaceuticalResearch

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

FDA approves Janssen’s Invokamet for diabetes

09-08-2014

The US Food and Drug Administration has approved US health care giant Johnson & Johnson subsidiary Janssen…

DiabetesInvokametInvokanaJanssenJohnson & JohnsonPharmaceuticalRegulationUSA

New products drive 2nd-qtr growth for Johnson & Johnson

New products drive 2nd-qtr growth for Johnson & Johnson

15-07-2014

Global health care products giant Johnson & Johnson, the first pharma to report second-quarter 2014 financial…

Business FinanceFinancialJohnson & JohnsonMonoclonal antibodiesPharmaceuticalPrednisoneUSA

1 to 25 of 254 results

Back to top